Epitalon
Also referenced as: Epithalon, AEDG peptide, epithalamin fragment
A four-amino-acid peptide central to longevity marketing and unsupported by modern controlled evidence.
- Evidence grade
- EExperimental / Limited Evidence
Experimental / Limited Evidence
- Regulatory status
- Not FDA Approved
- Human data
- Limited
No registered clinical trials identified
- Last reviewed
- September 1, 2026
Overview
Epitalon (Ala-Glu-Asp-Gly) derives from work on epithalamin, a pineal gland extract studied in the Soviet Union and Russia from the 1970s onward.
Reported effects on telomerase, melatonin rhythm and lifespan come from that research tradition. The absence of independent replication and modern trial reporting is the central problem with the evidence, not the age of the studies alone.
Why It's Being Studied
- Telomerase activity and cellular ageing in cell culture.
- Pineal function, melatonin rhythm and circadian regulation.
- Lifespan and tumour incidence in rodent models.
Mechanism of Action
Laboratory work suggested it may influence the enzyme that maintains the protective ends of chromosomes, and the pineal gland's melatonin rhythm.
Proposed mechanisms include induction of telomerase reverse transcriptase expression in somatic cell culture, epigenetic effects via short-peptide binding to promoter regions, and restoration of pineal melatonin secretion in aged animals. These mechanisms are not corroborated by contemporary independent work.
Research Areas & Routes Studied
- Cellular ageing
- Circadian rhythm
- Lifespan (animal)
- Subcutaneous injection (research)
- Intranasal (reported)
Evidence Summary
Claims rest largely on older Russian-language studies with limited methodological detail and little independent replication. Modern controlled human evidence is essentially absent.
Human clinical evidence
- Older Russian studies reported effects in elderly cohorts, but methods, randomisation and outcome definitions are poorly documented by modern standards.
Animal studies
- Rodent studies from the originating groups reported lifespan and tumour incidence effects.
In-vitro studies
- Telomerase induction reported in human somatic cell culture.
Anecdotal / community information
- Longevity communities report cycles of use. There is no established human dosing protocol and no controlled outcome data.
Reported Adverse Events in Research
- No modern safety dataset exists.
- Any compound proposed to activate telomerase raises theoretical oncological questions that have not been studied in people.
Limitations of Current Evidence
- Evidence concentrated in a single research tradition with minimal independent replication.
- Marketing claims about lifespan extension in humans are not supported by any controlled trial.
Documented Research Protocols
Epitalon — research context, not a human protocol
Explain the state of the Epitalon literature and why no protocol summary is defensible.
View documented protocol
Why It Is Used
- Sleep
Sleep Onset and Sleep Depth
Delta sleep-inducing peptide has the most promising name and some of the thinnest evidence on this site. That contrast is instructive.
Read the case study - Longevity
Healthy Ageing and Longevity
The category with the largest gap between ambition and evidence, and the one where the quality of the underlying research matters most.
Read the case study
Research References
- In-vitro study
Epithalon and telomerase activity in human somatic cells
- Animal study
Peptide epithalon and lifespan in animal models